Blog
RSS FeedPosted by Michael Wonder on 26 May 2016
NICE issues draft guidance for necitumumab (Portrazza)
26 May 2016 - NICE has released an appraisal consulation document for necitumumab for untreated advanced or metastatic, squamous non-small-cell ...
Posted by Michael Wonder on 25 May 2016
NICE updates guidance on the use of cabazitaxel in patients with hormone-relapsed metastatic prostate cancer treated with docetaxel
24 May 2016 - This guidance replaces NICE technology appraisal guidance on the use of cabazitaxel in patients with hormone-refractory metastatic ...
Posted by Michael Wonder on 25 May 2016
NICE recommends three diabetes treatments
24 May 2016 - The three drugs can all be used on their own if a person can’t use metformin or ...
Posted by Michael Wonder on 23 May 2016
Major parties clash over health
22 May 2016 - Coalition and Labor trade blows over PBS. ...
Posted by Michael Wonder on 23 May 2016
Proposal to award sole supply of bortezomib in DHB hospitals
As Velcade is currently the only funded brand of bortezomib, there would be no funded brand change resulting from this ...
Posted by Michael Wonder on 21 May 2016
Bill Shorten's $1b promise to keep medicine costs down
22 May 2016 - Labor is promising to keep the cost of prescription medicines down by officially ditching the Coalition's "medicine ...
Posted by Michael Wonder on 21 May 2016
Agenda for the 25 May 2016 TC meeting
22 May 2016 - The Transparency Commission will consider the (continued) reimbursement of voriconazole (Vfend), belatacept (Nulojix), bevacizumab (Avastin), bicalutamide (Casodex), ...
Posted by Michael Wonder on 20 May 2016
NICE recommends Novartis lung cancer drug Zykadia
20 May 2016 - NICE has recommended Novartis's Zykadia (ceritinib) for lung cancer in final guidance, after the manufacturer agreed to ...
Posted by Michael Wonder on 20 May 2016
Long term benefits of breast cancer drug pertuzumab too uncertain says NICE in draft guidance
20 May 2016 - NICE has today issued draft guidance not recommending pertuzumab (Perjeta, Roche) to treat HER2-positive breast cancer because ...
Posted by Michael Wonder on 19 May 2016
Sydney mother calls for cystic fibrosis drug Orkambi to be accessible for daughter
20 May 2016 - West Pymble six-year-olds Charli and Jasmine are twins, but their future lives look very different. ...
Posted by Michael Wonder on 18 May 2016
Getting effective cancer drugs to patients faster
18 May 2016 - The NHS and NICE are absolutely committed to ensuring people with cancer in England have access ...
Posted by Michael Wonder on 17 May 2016
Call for patient input on a submission from Boehringer Ingelheim for Praxbind
17 May 2016 - CADTH has received notice of a pending submission from Boehringer Ingelheim for Praxbind (idarucizumab) for the reversal ...
Posted by Michael Wonder on 17 May 2016
Brivaracetam in epilepsy: additional benefits not seen by IQWiG
17 May 2016 - No directly comparative study; the indirect comparisons are unusable. ...
Posted by Michael Wonder on 17 May 2016
CADTH publishes final report for anti–vascular endothelial growth factor drugs for retinal conditions
17 May 2016 - The recommendations report is now available for the CADTH project on anti–vascular endothelial growth factor drugs for ...
Posted by Michael Wonder on 17 May 2016
Vismodegib for basal cell carcinoma: additional benefits still not seen says Germany's IQWiG
17 May 2016 - Submitted data deemed to be unsuitable. ...